

Correction to: Afatinib in advanced NSCLC: a profile of its use

Emma D. Deeks¹ · Gillian M. Keating¹

Published online: 16 February 2018
© Springer International Publishing AG 2018

Correction to: *Drugs Ther Perspect*

<https://doi.org/10.1007/s40267-018-0482-6>

The article ‘Afatinib in advanced NSCLC: a profile of its use’, written by Emma D. Deeks and Gillian M. Keating, was originally published Online First without open access. After Online First publication, Boehringer Ingelheim Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Boehringer Ingelheim Pharmaceuticals, Inc. Further details may be found <http://www.medengine.com/Redeem/C10DF0600A95D8F5>. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article was corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40267-018-0482-6>.

✉ Emma D. Deeks
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand